Skip to main content
Top
Published in: Rheumatology International 8/2012

Open Access 01-08-2012 | Short Communication

Coexistence of primary aldosteronism and Hashimoto’s thyroiditis

Authors: Robert Krysiak, Bogusław Okopien

Published in: Rheumatology International | Issue 8/2012

Login to get access

Abstract

In light of research carried out in recent years, it seems that aldosterone may produce a complex proinflammatory effect. Theoretically, excessive aldosterone release may stimulate the development and/or progression of autoimmune disorders. In this article, we report a case of a female in whom primary aldosteronism coexisted with Hashimoto’s thyroiditis. Surgical removal of an aldosterone-producing tumor improved thyroid function and decreased thyroid autoimmunity. We describe in details diagnostic and treatment strategies applied in our patient and their impact on the course and outcome of thyroiditis. We also present monocyte and lymphocyte cytokine release in the index subjects before and after surgical treatment. We conclude that primary aldosteronism may exacerbate the clinical course of autoimmune thyroiditis and probably also of other autoimmune disorders.
Footnotes
1
Blood samples were collected when blood pressure was within normal limits (the patient was treated with verapamil and prazosin).
 
Literature
1.
go back to reference Mulatero P, Monticone S, Bertello C, Tizzani D, Iannaccone A, Crudo V, Veglio F (2010) Evaluation of primary aldosteronism. Curr Opin Endocrinol Diabetes Obes 17:188–193PubMedCrossRef Mulatero P, Monticone S, Bertello C, Tizzani D, Iannaccone A, Crudo V, Veglio F (2010) Evaluation of primary aldosteronism. Curr Opin Endocrinol Diabetes Obes 17:188–193PubMedCrossRef
2.
go back to reference Young W (2007) Primary aldosteronism: renaissance of the syndrome. Clin Endocrinol 66:607–618CrossRef Young W (2007) Primary aldosteronism: renaissance of the syndrome. Clin Endocrinol 66:607–618CrossRef
3.
4.
go back to reference Caturegli P, Kimura H, Rocchi R, Rose NR (2007) Autoimmune thyroid diseases. Curr Opin Rheumatol 19:44–48PubMedCrossRef Caturegli P, Kimura H, Rocchi R, Rose NR (2007) Autoimmune thyroid diseases. Curr Opin Rheumatol 19:44–48PubMedCrossRef
5.
go back to reference Lorini R, Gastaldi R, Traggiai C, Perucchin PP (2003) Hashimoto’s thyroiditis. Pediatr Endocrinol Rev 1(Suppl 2):205–211PubMed Lorini R, Gastaldi R, Traggiai C, Perucchin PP (2003) Hashimoto’s thyroiditis. Pediatr Endocrinol Rev 1(Suppl 2):205–211PubMed
6.
go back to reference Tanaka M, Izeki M, Miyazaki Y, Horigome M, Yoneda T, Tsuyuki S, Takami S, Aiba M (2002) Combined primary aldosteronism and Cushing’s syndrome due to a single adrenocortical adenoma complicated by Hashimoto’s thyroiditis. Intern Med Nov 41:967–971CrossRef Tanaka M, Izeki M, Miyazaki Y, Horigome M, Yoneda T, Tsuyuki S, Takami S, Aiba M (2002) Combined primary aldosteronism and Cushing’s syndrome due to a single adrenocortical adenoma complicated by Hashimoto’s thyroiditis. Intern Med Nov 41:967–971CrossRef
7.
go back to reference Okopień B, Krysiak R, Kowalski J, Madej A, Belowski D, Zieliński M, Herman ZS (2005) Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates. J Cardiovasc Pharmacol 46:377–386PubMedCrossRef Okopień B, Krysiak R, Kowalski J, Madej A, Belowski D, Zieliński M, Herman ZS (2005) Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates. J Cardiovasc Pharmacol 46:377–386PubMedCrossRef
8.
go back to reference Okopień B, Krysiak R, Kowalski J, Madej A, Belowski D, Zieliński M, Labuzek K, Herman ZS (2004) The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia. Atherosclerosis 176:327–335PubMedCrossRef Okopień B, Krysiak R, Kowalski J, Madej A, Belowski D, Zieliński M, Labuzek K, Herman ZS (2004) The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia. Atherosclerosis 176:327–335PubMedCrossRef
9.
go back to reference Brown RS (2009) Autoimmune thyroid disease: unlocking a complex puzzle. Curr Opin Pediatr 21:523–528PubMedCrossRef Brown RS (2009) Autoimmune thyroid disease: unlocking a complex puzzle. Curr Opin Pediatr 21:523–528PubMedCrossRef
10.
go back to reference Bendtzen K, Hansen PR, Rieneck K, Spironolactone/Arthritis Study Group (2003) Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-alpha and interferon-gamma, and has potential in the treatment of arthritis. Clin Exp Immunol 134:151–158PubMedCrossRef Bendtzen K, Hansen PR, Rieneck K, Spironolactone/Arthritis Study Group (2003) Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-alpha and interferon-gamma, and has potential in the treatment of arthritis. Clin Exp Immunol 134:151–158PubMedCrossRef
Metadata
Title
Coexistence of primary aldosteronism and Hashimoto’s thyroiditis
Authors
Robert Krysiak
Bogusław Okopien
Publication date
01-08-2012
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 8/2012
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-011-2032-6

Other articles of this Issue 8/2012

Rheumatology International 8/2012 Go to the issue